Project Grant R01HL175251
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$749K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to understand metabolic mechanisms underlying diabetic cardiomyopathy using human induced pluripotent stem cell (iPSC) models. The $433,824 award will fund the development and characterization of iPSC-derived cardiovascular cell types, including cardiomyocytes, endothelial cells, and fibroblasts, from both...
This $599,921 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of the RNA modification enzyme METTL3 in the cardiac benefits of exercise among individuals with diabetes. The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will conduct three specific aims to: 1) determine the role of METTL3 in the cardiac response to exercise in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $772,808 to Temple University to investigate the role of cardiomyocyte glutamine synthesis in heart failure development, fibroblast activation, and metabolic changes. The central hypothesis is that targeting cardiomyocyte glutamine synthesis can serve as a multipronged therapeutic strategy to improve bioenergetics, redox...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,204,160 to evaluate the AMPK-BACH1-NRF2 pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM). The primary goal is to determine if activating this signaling pathway can restore contractile function in multiple forms of inherited DCM, including those caused by mutations in myofilament and...
This federal Project Grant award, identified as R01HL171118, is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $847,164 grant supports research to investigate the underlying mechanisms of pathologic remodeling of the ventricular conduction system, particularly in the context of common acquired cardiomyopathies such as those seen in patients with hypertension, diabetes, and obesity. The research, conducted by...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,442 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The project, titled "Mechanistic Analysis of Aortic Growth and Remodeling Due to Hyperglycemia and Recovery," aims to determine how chronic hyperglycemia affects aortic biomechanics and mechanobiology, and whether restoring normoglycemia can...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of direct mitochondrial lactate oxidation in the failing heart. The $473,096 award, effective January 1, 2025 through November 30, 2029, will support research to quantify direct versus indirect mitochondrial lactate oxidation in healthy and failing heart...
This $543,268 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on RNA-mediated endotheliopathy - a key driver of diabetic vasculopathy. The primary awardee, Beckman Research Institute of the City of Hope, will identify novel long non-coding RNA (lncRNA) regulators of endothelial dysfunction, examine the role of N6-methyladenosine (m6A) RNA modification in diabetic endotheliopathy, and...
The federal Project Grant award for "LEUKOTRIENE B4 REGULATION IN HEART" is provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The $643,426 award will support research to determine how the leukotriene B4 receptor (LTB4R) signaling axis promotes ventricular arrhythmias in patients with type 2 diabetes. The research aims to validate LTB4 as a preclinical drug target and accelerate the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $242,310 to The Regents of the University of California, San Francisco (UCSF) to conduct a systems genomics approach to targeting glucose toxicity during pathological cardiomyocyte hypoxia. The project aims to gain a systems-level understanding of the pathways that facilitate adaptive and maladaptive metabolic changes in...